Notre conseil d'administration

Dorothea Wenzel est titulaire d'un doctorat en économie de la santé et en macroéconomie et d'une maîtrise en sciences commerciales et informatiques de l'université de Darmstadt en Allemagne. Elle a également obtenu des bourses à Harvard et a été étudiante invitée à l'université de Californie à Berkley. Dorothea Wenzel est citoyenne allemande. Elle a été nommée au conseil d'administration de H. Lundbeck A/S lors de l'assemblée générale annuelle de 2021. Elle préside le comité d'audit de H. Lundbeck A/S. 

Dorothea Wenzel est un membre indépendant du conseil d'administration. Elle a eu une longue carrière chez Merck KGaA, dont le siège est à Darmstadt, en Allemagne, où elle a récemment occupé, jusqu'en août 2021, le poste de vice-présidente exécutive et directrice de l'unité commerciale mondiale Surface Solutions. En 2018, elle a été directrice financière et responsable de la stratégie de la division Performance Materials, de 2014 à 2018, elle a dirigé la franchise commerciale mondiale Fertility de Merck, et de 2005 à 2013, elle a été directrice financière de la division Healthcare de Merck. Avant de rejoindre Merck, elle a travaillé chez McKinsey & Comp, dans une start-up de commerce électronique et pour une commission gouvernementale allemande.

Les qualifications particulières de Dorothea pour siéger au conseil d'administration de H. Lundbeck A/S comprennent une expérience impressionnante dans le domaine de la finance et de la stratégie dans plusieurs secteurs. Dorothea renforce les compétences du conseil d'administration en matière de finances et de transformation des entreprises afin de garantir que l'entreprise reste la mieux préparée pour l'avenir. 

Dorothea Wenzel est membre du conseil de surveillance (présidente du comité d'audit) du groupe Servier et membre du conseil d'administration de l'entreprise.

Lene Skole-Sørensen, BCom Finance, is a Danish citizen. She was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2015 Annual General Meeting. She is a member of H. Lundbeck A/S’ Remuneration & Nomination Committee and Scientific Committee.

Lene Skole-Sørensen is CEO at the Lundbeck Foundation, CEO at Lundbeckfond Invest A/S and Chair of the Board of Directors at LFI Equity A/S. Prior to joining the Lundbeck Foundation in 2014, Lene Skole-Sørensen was CFO at Coloplast A/S, where she was a member of the company’s executive management since joining in 2005. Lene Skole-Sørensen’s responsibilities included finance, IT, HR, communication, strategy and M&A. Before 2005, Lene Skole-Sørensen held various positions in the AP Moller-Maersk group, most recently as CFO of Maersk Company Ltd., London from 2000-2005.

Lene Skole-Sørensen’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech. 

Lene Skole-Sørensen is Chair of the Board of Directors of Ørsted A/S and Deputy Chair of the Board of Directors of Falck A/S, ALK-Abelló A/S and Nordea Bank Abp.

Lars Holmqvist, MSc in Business Administration, is a Swedish citizen. He was nominated for election to H. Lundbeck A/S' Board of Directors at the 2015 Annual General Meeting. He is a member of H. Lundbeck A/S' Audit Committee.

Lars Holmqvist was senior advisor within healthcare at Bain Capital Private Equity. He previously served as vice president responsible for sales and marketing at Pharmacia. In addition he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Inc, DAKO A/S and Agilent Technologies.

Lars Holmqvist’s special qualifications for serving on H. Lundbeck A/S' Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry.

Lars Holmqvist is Chair of the Board of Directors for Biovica International AB and a member of the Boards of Directors of the Lundbeck Foundation, ALK-Abelló A/S, Vitrolife AB, and Life Healthcare.

Jeffrey Berkowitz, Juris Doctor and BA in Political Science, is a US citizen. He was nominated for election to the H. Lundbeck A/S’ Board of Directors at the 2018 Annual General Meeting and is a member of H. Lundbeck A/S' Scientific Committee and since March 2019 a member of the Remuneration & Nomination Committee.

Jeffrey Berkowitz is currently the CEO of Real Endpoints, a leader in the development and implementation of proprietary tools to strengthen market access for biopharmaceutical companies. Prior to this, Jeffrey Berkowitz has recently served as an Executive Vice President of UnitedHealth Group (UNH), and CEO of their Optum International subsidiary since 2016. He served as an Executive Committee member and President of Pharma & Global Market Access at Walgreens Boots Alliance, Inc. from 2014 and served first as Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co, then as President of Walgreens Boots Alliance Development in the period 2010 to 2015. From 1998 to 2010, he held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. Prior to joining Schering-Plough, Jeffrey Berkowitz was a health care attorney for the international law firm Proskauer, LLP in New York and Washington, D.C.

Jeffrey Berkowitz’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include proven results and global experience with payers, pharmaceutical companies, specialty and retail pharmacies and drug distributors with deep experience in generic and branded procurement and inventory management, as well as pricing, reimbursement, specialty pharmacy distribution and health care strategies. He is a sought after thought leader and speaker in the area of pharmaceutical market access and reimbursement and has extensive public board and committee experience.

Jeffrey Berkowitz is Chair of the Board of PharmaTwoB. He is also a member of the Boards of Directors of Zealand Pharma A/S and Click Therapeutics. 

Dr. Santiago Arroyo, MD and PhD, is a US citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2021 Annual General Meeting and chairs H. Lundbeck's A/S' Scientific Committee.  

Dr. Arroyo has more than 30 years of experience in academic neurology and pharmaceutical research and development. As an academic neurologist, Dr. Arroyo held faculty positions at the Johns Hopkins Hospital, Hospital Clinic of Barcelona and the Medical College of Wisconsin where he was Associate Professor of Neurology. He has special expertise in pediatric and adult epilepsy and electrophysiology.

In 2003, Dr. Arroyo joined the pharmaceutical industry and has held a variety of positions in clinical research and development - most recently as Chief Development Officer at Bicycle Therapeutics. Prior to this, Dr. Arroyo served as Chief Medical Officer at Fulcrum Therapeutics and Momenta Pharmaceuticals. Before that, he held roles of Senior Vice President, Head of Clinical Research, and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc., Therapeutic Area Head for Neurosciences, Discovery Medicine, and Clinical Pharmacology at Bristol-Myers Squibb, and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development.

Dr. Arroyo’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his therapeutic and deep scientific expertise in neuroscience and beyond as well as strategic and business vision. 

Santiago Arroyo serves as a member of the Board of Directors at GlycoEra AG, Switzerland.

Lars Green has a MSc in business administration. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2025 Annual General Meeting.

Lars Green is a professional board member with more than 30 years of experience from the global pharmaceutical and life science industries, most recently as CFO of Novozymes from 2019 to 2023, where he stepped down following the successful formation of Novonesis through the merger with Chr. Hansen. Prior hereto, Lars spent more than 25 years with Novo Nordisk in various leadership roles, including regional CFO roles in both Japan and North America, and as head of Group Finance. The last two years he served on the Executive Management team with global responsibility for P&O, IT, Quality, Compliance and shared service functions.

Lars Green’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his international management experience in global pharmaceutical and life science companies. In addition, he has extensive experience in financial management, corporate governance, and interaction with investors and the financial markets.

Lars Green currently serves on the Board of Trustees of LEO Foundation and the Board of Directors of LEO Holding A/S, LEO Pharma A/S where he is also chairing the Audit Committee. He is member of the board of Pharmacosmos A/S, Green Housing ApS and Nordic Storm Holding A/S and is executive manager of Green & Niemann Invest Aps and LG Invest 2024 ApS.

Jakob Riis holds a Master's degree in Forestry and PhD in Econometrics from The Royal Veterinary and Agricultural University. He is a Danish citizen. He was nominated for election to H. Lundbeck A/S' Board of Directors at the 2023 Annual General Meeting. He is a member of H. Lundbeck A/S' Scientific Committee.

Jakob Riis is currently the CEO at Falck A/S and is considered as non-independent Lundbeck Board member, as the Lundbeck Foundation is a significant shareholder in the company. 

Jakob Riis has more than 25 years of experience in management and sales & marketing in the international healthcare industry. He previously worked at Novo Nordisk for 20 years in various positions in the commercial area (U.S. sales organization, Japan, Head of Marketing for more than a decade, and most recent as President of the North American business, member of the Executive Management). 

Jakob’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include proven track record in pharmaceutical value chain management from early-stage assets, production planning, registration trials, label negotiations, market access and global commercialization. In addition, he has extensive experience in operating in a listed company and market communication. 

Jakob Riis currently serves as Chair of the Board of Directors in Falck Healthcare A/S and Response A/S. He is also a member of the Board of Directors of the Danish Chamber of Commerce and Falck A/S subsidiaries. Furthermore, Jakob Riis is currently the CEO of Falck Danmark A/S and Adelca ApS.

Hossein Armandi, Process Technologist, is a Danish citizen. He has been employed at Lundbeck since 1995, holds a position as Research Technician and currently works in the research department of Translational Drug Metabolism and Pharmacokinetics.

Dorte Clausen, M.Sc. Molecular Biomedicine, is a Danish citizen. She has been employed at Lundbeck since 2012. She currently manages clinical studies within psychiatry and holds a position as Clinical Trial Manager, Specialist.

Dorte is a member of the Board at a Danish Union Pharmadanmark.

Lasse Skibsbye, Pharmacist and PhD in Medicine with specialty in cardiovascular safety pharmacology, is a Danish citizen.

He has been employed at Lundbeck since 2016 and currently holds a position as Principal Scientist and Safety Pharmacologist in the department of Exploratory Toxicology, Non-clinical Safety Research.

Lasse is a member of the board of the Danish Heart Association - local association “Hjerteforeningen” and member of the board of the Danish Pharmaceutical Society - section for Biopharmacy “Danmarks Farmaceutisk Selskab”.

Camilla Gram Andersson, M.Sc. in civil engineering, is a Danish citizen.

She has been employed at Lundbeck since 2005 and currently heads up Corporate Health, Safety & Environment (HSE) department, where she is responsible for the development of Lundbeck’s HSE strategy.

Camilla is a member of the Industrial Sectorial Board of Occupational Health and Safety (DI) and Specialized Committee of Chemistry (DI) as well as a member of the EHS expert group in European Federation of Pharmaceutical Industries and Associations (EFPIA).